JP6588004B2 - Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法 - Google Patents

Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法 Download PDF

Info

Publication number
JP6588004B2
JP6588004B2 JP2016502984A JP2016502984A JP6588004B2 JP 6588004 B2 JP6588004 B2 JP 6588004B2 JP 2016502984 A JP2016502984 A JP 2016502984A JP 2016502984 A JP2016502984 A JP 2016502984A JP 6588004 B2 JP6588004 B2 JP 6588004B2
Authority
JP
Japan
Prior art keywords
cells
seq
cd123car
nucleic acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514457A (ja
JP2016514457A5 (OSRAM
Inventor
フォーマン，スティーヴン・ジェイ
マルディロス，アーメン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51527938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6588004(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by City of Hope filed Critical City of Hope
Publication of JP2016514457A publication Critical patent/JP2016514457A/ja
Publication of JP2016514457A5 publication Critical patent/JP2016514457A5/ja
Application granted granted Critical
Publication of JP6588004B2 publication Critical patent/JP6588004B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2016502984A 2013-03-15 2014-03-14 Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法 Expired - Fee Related JP6588004B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/844,048 2013-03-15
US13/844,048 US9657105B2 (en) 2013-03-15 2013-03-15 CD123-specific chimeric antigen receptor redirected T cells and methods of their use
PCT/US2014/029109 WO2014144622A2 (en) 2013-03-15 2014-03-14 Cd123-specific chimeric antigen receptor redirected t cells and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019166068A Division JP6793800B2 (ja) 2013-03-15 2019-09-12 Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2016514457A JP2016514457A (ja) 2016-05-23
JP2016514457A5 JP2016514457A5 (OSRAM) 2016-06-30
JP6588004B2 true JP6588004B2 (ja) 2019-10-09

Family

ID=51527938

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016502984A Expired - Fee Related JP6588004B2 (ja) 2013-03-15 2014-03-14 Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法
JP2019166068A Expired - Fee Related JP6793800B2 (ja) 2013-03-15 2019-09-12 Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法
JP2020187011A Active JP7160882B2 (ja) 2013-03-15 2020-11-10 Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法
JP2022164487A Pending JP2022191388A (ja) 2013-03-15 2022-10-13 Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019166068A Expired - Fee Related JP6793800B2 (ja) 2013-03-15 2019-09-12 Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法
JP2020187011A Active JP7160882B2 (ja) 2013-03-15 2020-11-10 Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法
JP2022164487A Pending JP2022191388A (ja) 2013-03-15 2022-10-13 Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法

Country Status (14)

Country Link
US (3) US9657105B2 (OSRAM)
EP (2) EP3626247B1 (OSRAM)
JP (4) JP6588004B2 (OSRAM)
KR (4) KR102556831B1 (OSRAM)
CN (2) CN105392887B (OSRAM)
AU (3) AU2014228911A1 (OSRAM)
BR (1) BR112015023701B1 (OSRAM)
CA (1) CA2907216C (OSRAM)
DK (1) DK2968415T3 (OSRAM)
ES (1) ES2747099T3 (OSRAM)
IL (4) IL298332A (OSRAM)
MX (2) MX2015013195A (OSRAM)
RU (1) RU2711114C2 (OSRAM)
WO (1) WO2014144622A2 (OSRAM)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ES2828982T3 (es) 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
EP3021853A1 (en) 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
ES2767423T3 (es) * 2014-01-13 2020-06-17 Hope City Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CA3190002A1 (en) * 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
MX370272B (es) 2014-03-19 2019-12-09 Cellectis Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
LT3129470T (lt) * 2014-04-07 2021-07-12 Novartis Ag Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
CN107109420A (zh) 2014-07-21 2017-08-29 诺华股份有限公司 使用cll－1嵌合抗原受体的癌症治疗
EP3660042B1 (en) * 2014-07-31 2023-01-11 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
AU2015305531B2 (en) 2014-08-19 2021-05-20 Novartis Ag Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
RU2749922C2 (ru) * 2014-09-19 2021-06-21 Сити Оф Хоуп Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2
JP2017535284A (ja) * 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
TN2018000324A1 (en) 2015-01-23 2020-01-16 Sanofi Sa ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
AU2016212158B2 (en) 2015-01-26 2021-06-03 Allogene Therapeutics, Inc. mAb-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
EP3250611B1 (en) 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR102788389B1 (ko) * 2015-04-06 2025-03-31 서브도메인, 엘엘씨 드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도
US10100118B2 (en) * 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
JP2018516248A (ja) 2015-05-29 2018-06-21 アンフィヴェナ セラピューティクス，インク． 二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法
CN115925971A (zh) 2015-06-19 2023-04-07 塞巴斯蒂安·科博尔德 Pd-1-cd28融合蛋白及其在医学中的用途
WO2016210447A1 (en) 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
WO2017015490A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
SG10201912734PA (en) * 2015-08-05 2020-02-27 Yoo Young Pharm Co Ltd Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
CA2999037A1 (en) * 2015-09-23 2017-03-30 Cytoimmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
ES2809550T3 (es) * 2015-10-06 2021-03-04 Hope City Receptores de antígenos quiméricos dirigidos contra PSCA
WO2017064222A1 (en) 2015-10-16 2017-04-20 Ludwig-Maximilians-Universität München Cxcr6-transduced t cells for targeted tumor therapy
IL300420B2 (en) 2015-10-16 2024-09-01 Univ Columbia Compositions and methods for inhibition of lineage specific antigens
IL295398B2 (en) 2015-10-23 2025-01-01 Eureka Therapeutics Inc Antibody/T-cell receptor chimeric constructs and their uses
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
EP4074731A1 (en) * 2015-11-04 2022-10-19 City of Hope Chimeric antigen receptors targeting her2
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
SG11201805451TA (en) 2015-12-30 2018-07-30 Novartis Ag Immune effector cell therapies with enhanced efficacy
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
IL262321B2 (en) 2016-04-15 2024-09-01 Novartis Ag Preparations and methods for selective protein expression
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
CA3026858A1 (en) 2016-06-30 2018-01-04 F. Hoffmann-La Roche Ag Improved adoptive t-cell therapy
MX2019001469A (es) 2016-08-01 2019-10-02 Novartis Ag Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
WO2018081448A1 (en) * 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
CN110177809B (zh) * 2016-11-16 2023-11-03 埃博灵克斯股份有限公司 能够结合CD123和TCRα/β的T细胞募集多肽
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
WO2018176159A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
BR112020000273A2 (pt) * 2017-07-07 2020-07-14 Hanmi Pharm. Co., Ltd. proteína de fusão de enzima e seu método de preparação, composição farmacêutica, polinucleotídeo que codifica a proteína de fusão de enzima, vetor de expressão, transformante
MX2020002901A (es) 2017-09-19 2020-07-22 Massachusetts Inst Technology Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
KR20200069358A (ko) * 2017-10-25 2020-06-16 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
CA3079999A1 (en) * 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
IL314701A (en) 2017-11-14 2024-10-01 Arcellx Inc Multifunctional immune cell therapies
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
JP7285267B2 (ja) 2017-11-14 2023-06-01 アーセルクス インコーポレイテッド Ｄドメイン含有ポリペプチドおよびその使用
CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
GB201719646D0 (en) * 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN108276495B (zh) * 2018-01-24 2022-03-18 博生吉医药科技(苏州)有限公司 靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
EA202092044A1 (ru) 2018-03-14 2021-03-03 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные рецепторы антигена против cd33 и их применения
AU2019249221A1 (en) 2018-04-06 2020-10-22 The Regents Of The University Of California Methods of treating glioblastomas
WO2019195583A1 (en) * 2018-04-06 2019-10-10 Mustang Bio, Inc. Manufacturing methods for cell-based therapeutic compositions
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California Methods of treating egfrviii expressing glioblastomas
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
WO2020007593A1 (en) * 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210043562A (ko) 2018-07-10 2021-04-21 프레시전 인코포레이티드 Ror-1 특이적 키메라 항원 수용체 및 그의 용도
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
US20200222462A1 (en) * 2018-11-30 2020-07-16 Mustang Bio, Inc. Methods of treatment using decitabine and a cd123-targeted therapy
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020233284A1 (en) 2019-03-01 2021-09-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3935151A1 (en) 2019-03-08 2022-01-12 Klinikum der Universität München Ccr8 expressing lymphocytes for targeted tumor therapy
WO2020205751A1 (en) 2019-03-29 2020-10-08 City Of Hope Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CN110904048A (zh) * 2019-12-04 2020-03-24 合肥中科干细胞再生医学有限公司 一种car-cd123t2嵌合抗原受体t细胞及其应用
CN115066248A (zh) * 2019-12-16 2022-09-16 华盛顿大学 嵌合抗原受体树突状细胞(car-dc)及其制备和使用方法
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
KR20240096884A (ko) 2020-03-10 2024-06-26 매사추세츠 인스티튜트 오브 테크놀로지 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
CA3173981A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
CN113493772B (zh) * 2020-04-08 2022-10-18 华中农业大学 可分泌性表达免疫毒素的嵌合抗原受体修饰的免疫细胞
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN112079927B (zh) * 2020-09-18 2021-12-28 西安桑尼赛尔生物医药有限公司 一种cd123结合蛋白、含其的car及其应用
CN112521505B (zh) * 2020-12-11 2022-07-29 华道(上海)生物医药有限公司 抗cd123抗体及其应用
CN112646033B (zh) * 2020-12-16 2022-04-12 北京艺妙神州医药科技有限公司 靶向cd123的嵌合抗原受体及其用途
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US20250295693A1 (en) 2021-08-18 2025-09-25 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
JP2025500618A (ja) 2022-01-05 2025-01-09 ギャラ セラピューティクス ソシエダ リミタダ 抗ｃｄ８４抗体およびキメラ抗原受容体
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024094004A1 (zh) * 2022-11-03 2024-05-10 重庆精准生物技术有限公司 靶向cd123的全人源抗体及其应用
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP4630043A1 (en) 2022-12-06 2025-10-15 Dynamic Cell Therapies, Inc. Immune-activating complexes
EP4630446A1 (en) 2022-12-06 2025-10-15 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
CN117430721B (zh) * 2023-10-25 2024-06-25 北京景达生物科技有限公司 Cd123靶向car-nk细胞的制备及其应用
EP4599843A1 (en) 2024-02-09 2025-08-13 Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau Car and modified cd200r combination
WO2025255266A1 (en) 2024-06-05 2025-12-11 Dynamic Cell Therapies, Inc. Engineered polypeptides for immune cell activation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US20020102264A1 (en) 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
EP2394652A3 (en) * 2004-02-06 2012-10-24 Elan Pharmaceuticals Inc. Methods and compositions for treating tumors and metastatic disease
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
CN101952454B (zh) 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
US8822647B2 (en) * 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
CN102369291A (zh) 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 效应子功能降低的稳定Fc多肽及使用方法
CA2779526C (en) * 2009-11-03 2022-12-06 City Of Hope Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection
ES2656414T3 (es) 2010-09-08 2018-02-27 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
DK3424953T3 (en) * 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
KR20140127816A (ko) 2012-02-22 2014-11-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ES2767423T3 (es) 2014-01-13 2020-06-17 Hope City Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
RU2749922C2 (ru) 2014-09-19 2021-06-21 Сити Оф Хоуп Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2

Also Published As

Publication number Publication date
IL289883B (en) 2022-12-01
JP6793800B2 (ja) 2020-12-02
WO2014144622A3 (en) 2015-06-11
US20140271582A1 (en) 2014-09-18
AU2019202394A1 (en) 2019-05-02
JP2016514457A (ja) 2016-05-23
KR102506668B1 (ko) 2023-03-07
EP2968415A4 (en) 2017-01-04
JP2020010699A (ja) 2020-01-23
AU2021202705A1 (en) 2021-05-27
KR102416258B1 (ko) 2022-07-05
CN111926028A (zh) 2020-11-13
IL298332A (en) 2023-01-01
CN105392887A (zh) 2016-03-09
CA2907216C (en) 2024-02-27
EP3626247B1 (en) 2023-07-12
IL281562A (en) 2021-05-31
BR112015023701B1 (pt) 2022-01-11
EP2968415A2 (en) 2016-01-20
KR20220098048A (ko) 2022-07-08
IL281562B (en) 2022-02-01
KR20230035704A (ko) 2023-03-14
US11918606B2 (en) 2024-03-05
IL241668B (en) 2021-04-29
JP7160882B2 (ja) 2022-10-25
KR102297918B1 (ko) 2021-09-03
NZ712351A (en) 2021-07-30
RU2015140624A (ru) 2017-04-26
HK1222677A1 (zh) 2017-07-07
AU2014228911A1 (en) 2015-10-08
BR112015023701A2 (pt) 2017-07-18
CN105392887B (zh) 2020-05-29
CA2907216A1 (en) 2014-09-18
WO2014144622A2 (en) 2014-09-18
KR102556831B1 (ko) 2023-07-19
ES2747099T3 (es) 2020-03-10
MX2020001358A (es) 2020-08-20
US20200254023A1 (en) 2020-08-13
MX2015013195A (es) 2016-04-15
IL289883A (en) 2022-03-01
EP2968415B1 (en) 2019-07-31
RU2711114C2 (ru) 2020-01-15
US20170260277A1 (en) 2017-09-14
BR112015023701A8 (pt) 2020-03-10
JP2022191388A (ja) 2022-12-27
EP3626247A1 (en) 2020-03-25
US9657105B2 (en) 2017-05-23
JP2021036886A (ja) 2021-03-11
KR20210111879A (ko) 2021-09-13
IL289883B2 (en) 2023-04-01
US10660916B2 (en) 2020-05-26
KR20160012991A (ko) 2016-02-03
DK2968415T3 (da) 2019-10-21

Similar Documents

Publication Publication Date Title
JP7160882B2 (ja) Ｃｄ１２３特異的キメラ抗原受容体でリダイレクトしたｔ細胞およびそれらの使用方法
CN107074957B (zh) 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
CA3133633A1 (en) Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
WO2023056429A1 (en) Anti-nmdar2b antibodies, antibody-drug conjugates, and chimeric antigen receptors, and compositions and methods of use
HK40026837A (en) Cd123-specific chimeric antigen receptor redirected t cells and methods of their use
HK1222677B (zh) Cd123特异性嵌合抗原受体重导向性t细胞及其使用方法
WO2023215746A2 (en) Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190911

R150 Certificate of patent or registration of utility model

Ref document number: 6588004

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees